NCT06997029 2026-03-16
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
Clinical Trials
10 trialsNCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT05238922 2026-02-10
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT04360941 2026-01-21
PAveMenT
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT03454035 2025-09-11
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT04606446 2025-08-13
KAT6
Pfizer
Phase 1 Recruiting
NCT06113809 2025-06-03
Palbociclib and Pembrolizumab in Sarcoma
University of Iowa
Phase 1 Recruiting
NCT04996160 2025-01-24
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Stanford University
Phase 1 Recruiting
NCT06654297 2024-12-11
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT06307249 2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1 Recruiting